Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AM-111 in Acute Inner Ear Hearing Loss
NCT02561091Phase 3Completed
- Sponsor
- Altamira Therapeutics
- Start
- Nov 2015
- Primary completion
- Sep 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of brimapitide in idiopathic sudden sensorineural hearing loss (ISSNHL), sponsored by Altamira Therapeutics. Started Nov 2015; status: completed.
02
Drugs
brimapitide
03
Conditions
idiopathic sudden sensorineural hearing loss (ISSNHL)
Beyond the preview
Go deeper on NCT02561091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02561091.